Merck KGaA CEO Belén Garijo to leave next May, when electronics unit leader...
Belén Garijo will hand over the CEO post at Merck KGaA to the German healthcare conglomerate's electronics unit leader on May 1, 2026, the company said Thursday. Kai Beckmann, who's been ...
View ArticleEpic embraces the newfound attention of its AI tools
When electronic health record giant Epic revealed a suite of AI tools at its annual conference in August, the healthcare industry was closely watching. But a lot of it is not entirely new, VP of ...
View ArticleUK government reveals £50M R&D fund as it attempts to assuage drugmakers’...
After weeks of hearing biopharma companies criticize the UK’s life sciences environment, the government is looking to turn down the heat. The UK government said on Thursday it has allocated ...
View ArticlePfizer's Metsera deal could spark more M&A for pharmas 'tiptoeing into obesity'
Pfizer's up to $7.3 billion acquisition of Metsera earlier this week was the first big pharma purchase of an obesity biotech since Roche’s buyout of Carmot Therapeutics in late 2023. Analysts told...
View ArticleCatalent moves into new HQ; Fujifilm opens factory in North Carolina
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Catalent opened its new headquarters in Tampa, FL, on Monday. Earlier...
View ArticleVirtual team of researchers, advocates try to break 40-year logjam in...
When Mac Tichenor’s son Willie died of osteosarcoma at the age of 19 back in 2006, oncologists still relied on a decades-old chemo regimen called MAP — high-dose methotrexate, combined with doxorubicin...
View ArticleKardigan gets the rights to a MyoKardia drug; Lilly stops Phase 2 trial for...
Plus, news about uniQure, MBX Biosciences, KalVista, Volastra, Basilea Pharmaceutica, Gossamer Bio, Respira Therapeutics, Sanofi, Immuneering and Heidelberg Pharma: 🫀 Kardigan reveals its pipeline: The...
View ArticleBiogen calls it quits on AAV gene therapy, again
Biogen is ending its gene therapy work that relies on adeno-associated viruses, or AAVs, the company confirmed to Endpoints News, making it the latest pharma to walk away from the viral-based delivery...
View ArticlePost Hoc Live: How the US can compete with China biotech, with Scott Gottlieb
Over the last few months on Post-Hoc Live, we’ve done shows about the rapid rise of China’s biotech industry, and how some in the industry are pushing for restrictions to block or slow competition....
View ArticleNovartis escalates court fight against Maine 340B law
The fight over the use of “contract pharmacies” in the 340B drug discount program has reached another federal appeals court. Novartis asked the US Court of Appeals for the First Circuit this week to...
View ArticleFDA approves Lilly's oral SERD in second-line breast cancer
The FDA on Thursday approved Eli Lilly’s imlunestrant, an oral SERD, to treat patients with a certain kind of breast cancer. The drug will be branded as Inluriyo and is approved ...
View ArticleTwo new ARPA-H programs aim to boost genetic medicine access
The federal agency that aims to fast-track medical breakthroughs has launched two new initiatives around making genetic medicines more widely available. One program, announced by the Advanced Research...
View ArticleWhite House weighs broad drug pricing announcement
The White House is considering a significant event as soon as next week to tout its efforts to reduce US drug prices, roping in several different initiatives, according to several sources familiar with...
View ArticleTrump threatens 100% tariff on pharma products next week for companies not...
President Donald Trump said that he'll slap a 100% tariff on drugmakers' products unless the companies are building a manufacturing plant in the US. In a Truth Social post on Thursday ...
View ArticleCrinetics gets first FDA approval as Palsonify is cleared for rare hormonal...
Crinetics won FDA approval for Palsonify to treat a rare condition that occurs when the pituitary gland produces too much growth hormone. The company said Thursday that Palsonify, also known as ...
View ArticleMerck KGaA’s top-level changes continue with CEO transition; Incyte hires...
→ Major personnel moves have been a recurring theme at Merck KGaA in recent months, and there are none bigger than CEO Belén Garijo’s upcoming departure. On May 1, 2026, Garijo
View ArticleGet your CVR: Backloaded acquisitions come into focus following Metsera,...
As pharma companies become even more risk-averse, biotechs that have been getting acquired are increasingly finding that for shareholders to get the full deal value, their assets must reach their...
View ArticlePatient groups push abandoned rare disease gene therapy toward clinical trial
Two rare disease groups have produced the key funding needed to make a gene therapy for a very rare neurological disease. The treatment could reach patients as soon as next year after it was previously...
View ArticleLilly's Kisunla gets EU approval; Sanofi expands insulin discount program
Plus, news about Regeneron's Evkeeza and Cure Alzheimer's: 🇪🇺 EU approves Eli Lilly’s Kisunla: The Alzheimer’s drug originally earned a negative CHMP opinion in March but was re-evaluated in June. Lilly
View ArticleTrump’s new tariff threat throws months of deals and negotiations into...
After months of bullying, flattery and negotiations, President Donald Trump's White House had stitched together a series of deals with the pharma industry and foreign nations that would meet several of...
View ArticleAlmost 30% of industry-funded research goes unpublished, new study says
When it comes to releasing clinical trial results, the pharmaceutical industry has always been considered the villain: burying the bad results and putting out press releases about the good ones. But a...
View ArticleMission BioCapital raises $134M for sixth biotech investment fund
Mission BioCapital has collected $134 million for its sixth investment fund, according to an SEC document filed Friday morning. The firm invests in early-stage biotech companies like March Biosciences,...
View ArticleAppeals court rejects Novartis' attempt to block Entresto generics
The FDA lawfully approved a generic version of Novartis' blockbuster heart drug Entresto, a federal appeals court held Friday. The US Court of Appeals for the DC Circuit affirmed a district court...
View Article